Parkinson's disease is a degenerative disorder of the central nervous system. The motor symptoms of Parkinson's disease result from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain; the cause of this cell death is unknown. Homocysteine (Hcy) is a non-protein amino acid. It is a homologue of the amino acid cysteine. The elevated levels of homocysteine in plasma have been associated with a number of disease states. Hcy (2 µmol / µl) was injected intracerebroventricular (i.c.v) in rats, five days later, the locomotor activity was measured with open field apparatus, Also apoptosis was investigated in substantia nigra cells by immunohistochemical analysis. Hcy could decrease locomotor activities significantly in rats as well as it could induce apoptosis in substantia nigra cells. These results suggest that Hcy is a neurotoxic metabolite and may induce cell death in some nuclei in the brain.
arkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease (AD) (1) Also, it is progressive and leads patients to a debilitating condition and includes as well extensive dopaminergic neuron degeneration in the substantia nigra pars compacta (2) and the other subcortical nuclei with motor and non-motor symptoms. Motor symptoms are discriminated by hypokinesia, rigidity, tremor, and postural imbalance (3) and non-motor symptoms including autonomic dysfunction, neuropsychiatric problems, and sensory and sleep difficulties, which are common. Homocysteine is considered a risk factor for multiple neurological disorders including AD and PD (4, 5, 6) . Homocysteine (Hcy); a sulfur containing amino acid derived from the metabolism of methionine, is an independent risk factor for cardiovascular disease (7) . The thiol group of Hcy is readily oxidized in plasma and culture medium, resulting in the generation of reactive oxygen species (ROS). Moreover, Hcy has the ability to inhibit the expression of antioxidant P (10) . In spite of many researches in this area, the molecular mechanism of homocysteine-induced neurotoxicity has not been completely established at present.
Materials and Methods

Drugs and Biochemical reagents
D-L-Homocysteine was purchased from
Sigma-Aldrich, Germany. Ketamine and xylazine were obtained from ALFASAN Co, Netherlands. which was attached to a 5-µl Hamilton syringe.
Behavioral and histo chemical analyses were performed five days after Hcy injection in rats.
Measurement of Locomotors Activities
The effects of Hcy on the rats' behavior were studied by an open-field apparatus. All experiments were carried out 5 days after Hcy 
Brain Histopathological Analysis
At the end of the behavioral experiments, the rats were deeply anesthetized with a high dose of ketamine (150 mg/kg) and perfused through the ascending aorta with 50-100 ml of 0.9% saline 
Results
Locomotor Activity
I.c.v. treatment of homocysteine (2 µmol)
decrease the locomotor activity (total distance and velocity) compared to control group (F(1, 10) = 517.5, p<0.001) for total distance and (F(1, 10)=129.5, p<0.001) for velocity (Fig. 1) .
Bax/Bcl-2
To determine whether homocysteine leads to changes in Bcl-2 family protein levels in the rat brain, we examined the Bcl-2 and Bax protein immunostaining. As shown in fig. 2 , Bax protein was detected in control animals and in homocysteine animals; Bax immunostaining significantly increased in control groups (Fig. 2, 3 ), (F (1, 10) = 1525.5, p<0.001). In contrast with Bax, Bcl-2 staining showed a vigorous expression of this anti apoptotic protein in control group, and this refers to the constitutive expression of Bcl-2 protein in normal conditions In fig. 4 , the Bax/Bcl-2 ratio was calculated for SN tissue as explained above.
The results showed that in control group, this ratio is lower than homocysteine group which were significantly increased (F (1, 10) = 97.93, p<0.001).
Discussion
The aim of this study was to investigate the neurotoxic effect of Hcy in SN cells in the rat brain, 
